U.S. FDA accepts sNDAs for Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)

23 January 2019 - Potential new indication would expand use to allow treatment-experienced adults living with HIV-1 whose virus is suppressed ...

Read more →

Decisions relating to the funded brands of some anti-retroviral treatments for HIV

20 December 2018 - PHARMAC is pleased to announce decisions to award sole supply for seven anti-retroviral treatments used in ...

Read more →

FDA announces pilot program with WHO to expedite review of HIV drug applications

30 November 2018 - The U.S. FDA today announced a plan to work with the WHO to pilot a process to ...

Read more →

Proposal to award sole supply and change some anti-retroviral brands

16 October 2018 - PHARMAC is seeking feedback on a proposal to make several changes to funding of anti-retroviral therapies ...

Read more →

Gilead receives approval in Canada for Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for the treatment of HIV-1 infection

12 July 2018 - Gilead Sciences Canada today announced that Health Canada has granted a notice of compliance for Biktarvy (bictegravir ...

Read more →

Rapid rise in anti-HIV PrEP pills linked to drop in condom use

7 June 2018 - PrEP availability may play a part in men’s complacency about the chances of becoming infected, study suggests. ...

Read more →

New medicine to help end the transmission of HIV

21 March 2018 - The Australian Government is taking a critical step in helping end the transmission of HIV infection in ...

Read more →

National PreP service would be cost effective, research finds

20 October 2017 - Providing pre-exposure prophylaxis treatment to men who have sex with men at high risk of contracting ...

Read more →

TGA approves Odefsey

30 August 2016 - The TGA has approved Gilead's combination product for HIV-1 infection Odefsey. ...

Read more →

Janssen submits marketing authorisation application for darunavir-based single tablet regimen for treatment of HIV-1 to European Medicines Agency

12 September 2016 - Janssen today announced the submission of a Marketing Authorisation Application to the EMA, seeking approval for ...

Read more →

Proposal relating to two HIV treatments (Tivicay and Kivexa)

9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and ...

Read more →

CADTH recommends the reimbursement of Descovy (emtricitabine with tenofovir alafenamide fumarate)

24 August 2016 - CADTH is in favour of the reimbursement of Gilead's new dual combination product for HIV-1 infection. ...

Read more →

CADTH recommends reimbursement of Truvada for PrEP

24 August 2016 - The recommendation comes with conditions. ...

Read more →

Brisbane sees 30% drop in HIV infection over 5 year period; HIV medicine Truvada still not on PBS

23 August 2016 - The combination HIV medicines that has led to a significant drop in the number of HIV cases ...

Read more →

European Commission grants marketing authorization for Gilead’s once-daily Truvada for reducing the risk of sexually acquired HIV-1

22 August 2016  - Truvada is the first anti-retroviral medicine to be licensed in Europe for pre-exposure prophylaxis, in combination with ...

Read more →